Brought to you by 
Lundbeck licenses two Teva Parkinson's disease drugs
13 Dec 1999
Executive Summary
Danish CNS drug developer H. Lundbeck in collaboration with Teva (Israel's largest pharmaceutical company), will co-develop the latter's Parkinson's disease drugs: the Phase III Rasagiline and TV 1203, in Phase II. Lundbeck will get exclusive European marketing rights from Teva, which will retain rights in all other territories worldwide.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lundbeck licenses two Teva Parkinson's disease drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice